-
Anti-ROR1 Antibody: Mechanism to Assay Design
2026-08-17
Anti-ROR1 Antibody (Zilovertamab) enables target-specific investigation of ROR1 biology, while a recent deoxynivalenol study illustrates how causal perturbation can strengthen mechanistic assays. This guide connects binding validation, pathway analysis, and evidence boundaries without conflating oncology and hepatotoxicity models.
-
AICAR for Reliable AMPK Assays
2026-08-17
This scenario-driven guide explains how AICAR (5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside), SKU A8184, can improve experimental control in cell viability, proliferation, cytotoxicity, and metabolic-stress studies. It covers assay compatibility, solution preparation, interpretation of AMPK-dependent effects, and practical vendor-selection criteria.
-
CCT007093: A Contextual PPM1D Inhibitor Guide
2026-08-16
CCT007093 is a PPM1D inhibitor for testing how phosphatase control shapes p38 signaling, cancer-cell viability, and pyroptosis. This guide focuses on causal assay interpretation across breast cancer and kidney-injury models rather than repeating a conventional stepwise protocol.
-
Fangchinoline Restores Lysosomal Defense Against H1N1
2026-08-15
Cheng and colleagues identify fangchinoline as a lysosome-targeted antiviral compound that restores TFEB-driven lysosomal gene expression and interferes with H1N1 entry. The study combines Connectivity Map screening, transcriptomic analysis, organelle assays, stage-resolved infection experiments, and in vivo validation to define a host-directed mechanism against influenza.
-
Annexin V-Cy5/DAPI Apoptosis Kit Guide
2026-08-14
A scenario-driven guide to using the Annexin V-Cy5/DAPI Apoptosis Kit (SKU K2255) for rapid phosphatidylserine-based apoptosis detection and apoptosis and necrosis differentiation. It connects practical staining, flow cytometry, microscopy, controls, and interpretation to mechanistic findings in leukemia research.
-
Melittin as a GPCR Lens for Translational GBM Research
2026-08-14
Glioblastoma research increasingly requires tools that connect lipid metabolism, GPCR signaling, tumor migration, and regulated cell death. This thought-leadership article positions Melittin as a bioactive peptide and signal transduction modulator for testing those connections, while distinguishing hypothesis generation from validated mechanism. It integrates findings from the miR-18a/ALOXE3 study with practical guidance on controls, sample handling, pathway readouts, and translational interpretation. The goal is not to present Melittin as a GBM therapy, but to show how a carefully controlled Gs/Gi perturbation strategy can sharpen mechanistic decisions in cancer biology research.
-
2'3'-cGAMP: Practical STING Assay Workflows
2026-08-13
Build reproducible cGAS-STING experiments with a water-soluble, high-affinity endogenous ligand for pathway activation, benchmarking, and delivery studies. This guide connects direct cell assays with lipid nanoparticle workflows inspired by pancreatic cancer research.
-
Necrostatin 2 (Nec-2): Reliable Cell Death Assays
2026-08-13
This scenario-driven guide explains how Necrostatin 2 (Nec-2), SKU A3652, can support controlled necroptosis inhibition, pathway testing, and interpretation of cell-death assays. It also addresses formulation, storage, cross-talk with ferroptosis research, and practical criteria for selecting a reliable research reagent.
-
Annexin V-Cy5/DAPI Apoptosis Kit Workflow
2026-08-12
Build a rapid, two-parameter cell death workflow that separates phosphatidylserine exposure from loss of membrane integrity in as little as 10–20 minutes. This guide applies the Annexin V-Cy5/DAPI Apoptosis Kit to leukemia drug-response studies, mechanistic experiments, and reproducible apoptosis and necrosis differentiation.
-
JNJ-26481585: An Assay-First HDAC Strategy
2026-08-12
Explore how JNJ-26481585 (Quisinostat) connects HDAC inhibition with histone acetylation, TRIM21 regulation, ERK signaling, and apoptosis. This assay-centered guide translates mechanistic findings into practical workflows for proliferation, resistance, and tumor growth inhibition studies.
-
P2RX1-Driven Mitochondrial Apoptosis in Ph+ ALL
2026-08-11
Li et al. identify P2RX1 as a regulator of mitochondrial apoptosis in Philadelphia chromosome-positive acute lymphoblastic leukemia, linking calcium/CaMKII activation with suppression of PI3K/Akt signaling. The study provides a mechanistic framework for understanding how P2RX1 expression may influence tyrosine kinase inhibitor response, while also highlighting important distinctions between prognostic association and therapeutic effect.
-
Letrozole: Mechanism, Evidence, and Research Workflow
2026-08-11
Letrozole is a potent, reversible non-steroidal aromatase inhibitor used to suppress estrogen biosynthesis in experimental systems. Its type II heme-binding mechanism supports breast cancer research, while vendor-reported neuroendocrine and synaptic effects require model-specific validation.
-
P2RX1–CaMKII Apoptosis Signaling in Ph+ ALL
2026-08-10
Li et al. identify a P2RX1–calcium/CaMKII pathway that suppresses PI3K/Akt signaling and promotes mitochondrial apoptosis in Philadelphia chromosome-positive acute lymphoblastic leukemia. The study links purinergic signaling to tyrosine kinase inhibitor responsiveness, while its cell-line and database findings support further validation in primary and treatment-resistant Ph+ ALL models.
-
Gallein and Gβγ Control of GPCR Metabolism
2026-08-09
Gallein is a G protein βγ subunit inhibitor that can help test whether metabolic GPCR signals converge on Gβγ-dependent effectors. This article connects the compound’s established oncology, immunology, and cardiac models with new assay logic inspired by lactate–GPR81–FARP1 signaling.
-
NSP15 Screening Reveals Natural Product Inhibitors
2026-08-08
This 2021 study used structure-based virtual screening and molecular dynamics simulations to prioritize natural products against the SARS-CoV-2 NSP15 endoribonuclease. Thymopentin and oleuropein emerged as the most stable, high-affinity candidates, but the computational findings require biochemical and cellular validation before therapeutic conclusions can be drawn.